These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 11292288)
1. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection. Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288 [TBL] [Abstract][Full Text] [Related]
2. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
3. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383 [TBL] [Abstract][Full Text] [Related]
4. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713 [TBL] [Abstract][Full Text] [Related]
5. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions. Bishop DK; Chan Wood S; Eichwald EJ; Orosz CG J Immunol; 2001 Mar; 166(5):3248-55. PubMed ID: 11207279 [TBL] [Abstract][Full Text] [Related]
6. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. Kemp RA; Ronchese F J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817 [TBL] [Abstract][Full Text] [Related]
7. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. Helmich BK; Dutton RW J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800 [TBL] [Abstract][Full Text] [Related]
8. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212 [TBL] [Abstract][Full Text] [Related]
9. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652 [TBL] [Abstract][Full Text] [Related]
10. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma. Braun MY; Desalle F; Le Moine A; Pretolani M; Matthys P; Kiss R; Goldman M Eur J Immunol; 2000 May; 30(5):1290-6. PubMed ID: 10820374 [TBL] [Abstract][Full Text] [Related]
11. Visualization of the in vivo generation of donor antigen-specific effector CD8+ T cells during mouse cardiac allograft rejection: in vivo effector CD8+ T cell generation during allograft rejection. Gilot BJ; Hara M; Jones ND; van Maurik A; Niimi M; Hadjianastassiou V; Morris PJ; Wood KJ Transplantation; 2000 Feb; 69(4):639-48. PubMed ID: 10708123 [TBL] [Abstract][Full Text] [Related]
12. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype. Halverson DC; Schwartz GN; Carter C; Gress RE; Fowler DH Blood; 1997 Sep; 90(5):2089-96. PubMed ID: 9292548 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285 [TBL] [Abstract][Full Text] [Related]
14. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754 [TBL] [Abstract][Full Text] [Related]
15. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. Li L; Sad S; Kägi D; Mosmann TR J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975 [TBL] [Abstract][Full Text] [Related]
16. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Chan SY; DeBruyne LA; Goodman RE; Eichwald EJ; Bishop DK Transplantation; 1995 Apr; 59(8):1155-61. PubMed ID: 7732563 [TBL] [Abstract][Full Text] [Related]
17. Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Nagano H; Libby P; Taylor MK; Hasegawa S; Stinn JL; Becker G; Tilney NL; Mitchell RN Am J Pathol; 1998 May; 152(5):1187-97. PubMed ID: 9588888 [TBL] [Abstract][Full Text] [Related]
18. Donor IFN-gamma receptors are critical for acute CD4(+) T cell-mediated cardiac allograft rejection. Wiseman AC; Pietra BA; Kelly BP; Rayat GR; Rizeq M; Gill RG J Immunol; 2001 Nov; 167(9):5457-63. PubMed ID: 11673565 [TBL] [Abstract][Full Text] [Related]
19. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495 [TBL] [Abstract][Full Text] [Related]